The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • LBT Innovations (LBT) pens a deal with AstraZeneca to undertake full product development of its APAS Pharma artificial intelligence software
  • The APAS Pharma analysis module will be developed to identify microbial growth on settle plates used in sterility monitoring during drug manufacturing
  • Under the project, AstraZeneca will fund the development of the APAS Pharma analysis module and validate the final product for their processes
  • The project is expected to cost approximately $1 million, with payment received based on achieving a series of technical milestones
  • Shares in LBT Innovations are up 18.5 per cent, trading at 6.4 cents as of 10:57 am AEDT

LBT Innovations (LBT) has been engaged by AstraZeneca to undertake a full product development project for its APAS Pharma product.

The project will use the company’s new APAS Pharma analysis module on the APAS independence instrument.

Under the project, AstraZeneca will fund the development of the APAS Pharma analysis module and validate the final product for their processes.

The project is expected to cost approximately $1 million, with payment received based on achieving a series of technical milestones.

LBT CEO and Managing Director Brent Barnes said this partnership is exciting for the company.

“AstraZeneca leads this field and is looking to innovate its processes and set the standard for others to follow,” he said.

“Our APAS technology is ideally suited for the application of microbial quality control,
able to improve consistency of results and drive standardisation across manufacturing sites.”

It is expected that an APAS independence instrument will be deployed to AstraZeneca to support data collection and testing as part of the development for the new APAS Pharma analysis module.

The analysis module will be developed to identify microbial growth on settle plates
used in sterility monitoring during drug manufacturing to create the final product.

Shares in LBT Innovations were up 18.5 per cent, trading at 6.4 cents as of 10:57 am AEDT.

LBT by the numbers
More From The Market Online
The Market Online Video

Issues emerging as Australian companies tackle critical minerals challenge

Most critical minerals deposits with higher grades have been discovered & mined - or are being…
The Market Online Video

ASX Market Close: Enthusiasm pushes Index higher, as all eyes on US CPI data out tonight | October 10, 2024

Investor’s enthusiastic mood reflects sustained expectation of further rate cuts in the United States, and Chinese…
Wall Street and American flag

Tonight’s US CPI data could set the tone for November. What are markets expecting?

The US Fed cut rates by -50bps a few weeks ago, then more recently, we learned…
The Market Online Video

Recce progresses testing of gel to treat bacterial skin infections

Recce Pharmaceuticals Ltd has reached an important milestone in testing of its R327G gel to treat…